827 results on '"Joore, Manuela A."'
Search Results
2. A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations
3. Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
4. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
5. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
6. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework
7. Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
8. Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
9. Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands
10. The added value of risk assessment and subsequent targeted treatment for epileptic seizures after stroke: An early-HTA analysis
11. Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
12. Headroom Analysis for Early Economic Evaluation: A Systematic Review
13. Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
14. Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
15. Bilateral vestibulopathy patients’ perspectives on vestibular implant treatment: a qualitative study
16. The value of correctly diagnosing axial spondyloarthritis for patients and society
17. Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer
18. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
19. Effectiveness of the Assessment of Burden of Chronic Conditions (ABCC)-tool in patients with asthma, COPD, type 2 diabetes mellitus, and heart failure: A pragmatic clustered quasi-experimental study in the Netherlands
20. Navigating the Reimbursement Conundrum in Drug Repurposing: Balancing Access, Pricing, and Innovation
21. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
22. The effectiveness of health education interventions on cervical cancer prevention in Africa: A systematic review
23. Quality of life in a real-world cohort of advanced breast cancer patients : a study of the SONABRE Registry
24. Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
25. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
26. State of the ART? Two New Tools for Risk Communication in Health Technology Assessments
27. Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation
28. Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study
29. Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands
30. BMI trajectories after primary school-based lifestyle intervention: Unravelling an uncertain future. A mixed methods study
31. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making
32. Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
33. Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review
34. The potential cost‐effectiveness of roflumilast drug treatment in mild cognitive impairment
35. Response to “UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP”
36. An investigation of age dependency in Dutch and Chinese values for EQ-5D-Y
37. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
38. Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments
39. Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
40. Whole genome sequencing in oncology: using scenario drafting to explore future developments
41. Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
42. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
43. Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
44. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
45. Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
46. Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”
47. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
48. Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
49. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis
50. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.